Abstract:Sustained stress leads to series of changes in the brain, firstly through the activation of hypothalamus–pituitary–adrenal (HPA) axis and sympathetic nervous system (SNS) axis, then the release of glucocorticoid (GCs) and catecholamines (CAs), respectively. The circulating GCs can cause neuronal injury and even the loss of neurons, accompanying the increased level of proinflammatory cytokines in the circulation. Chronic stress has been linked to various diseases, especially mood disorders and neuropsychiatric disorders, mainly mediated by the limbic system. Yet the relationship between chronic stress and neurodegenerative disorders such as Alzheimer disease (AD) and Parkinson’s disease (PD) is unknown. It has been found that depression often precedes PD symptoms in clinical subjects [1], while many PD patients present with depression symptoms as well [2,3]. A recent study published in Molecular Psychiatry by Hemmerle et al. [4] addressed this point by subjecting 6-OHDA-lesioned rats to the chronic stress, and they found that chronic stress exacerbates the loss of dopamine neurons induced by 6-OHDA injection. The results strongly argued that chronic stress may function as an important factor in the development of PD and potentially other neurodegenerative diseases. Hemmerle et al. generated a rat model of PD by unilateral 6-OHDA injection, which produces selective toxicity to dopamine neurons, especially in substantia nigra. The dopamine neuron loss leads to motor behavior deficits, as reflected by the forelimb asymmetry test, because the loss of dopamine neurons would lead to impaired usage of the contralateral limb, while the severity of dopamine neuron loss was histologically examined by TH staining [4]. When the rats were subjected to chronic unpredictable stress, the authors found that the rats would demonstrate increased forelimb asymmetry (suggestive of worse behavior), which correlated with increased dopamine neuron loss (decreased TH staining). Interestingly, the chronic stress alone did not induce loss of dopamine neurons, and the stress had to occur simultaneously with toxin exposure [4], suggesting that the stress might act adjuvantly with the toxin or increase the vulnerability of the neurons. In clinical studies, depression as the most common disease caused by chronic stress may occur prior to PD symptoms [1] and may indicate worse prognosis for PD patients [5]. Yet it should be noted that the loss of dopamine neurons could occur much earlier to the motor symptoms [6] and therefore may be concurrent with the depression as well. What are the potential mechanisms linking stress and increased dopamine neuron loss? It is possible that glucocorticoid contributes to this process, partly through the glucocorticoid receptors (GRs) on the microglia, because MPTP-induced neurotoxicity was less in mice whose GRs were knocked down selectively on microglial cells [7]. In addition, GRs on dopamine neurons regulate the activity of the cells and might sensitize the neurons through excitotoxicity [8]. On the other hand, there is evidence suggesting that the depression can be caused by loss of dopaminergic innervation during PD progression [2], acting as the downstream of PD pathology. It is believed that the mesolimbic and mesocortical dopaminergic pathways that are disrupted in PD would contribute to the depression symptoms [3]. Indeed, a recent study has shown that selective activation of midbrain dopamine neurons with optogenetic tech-

Nanowired delivery of dl-3-n-butylphthalide with antibodies to alpha synuclein potentiated neuroprotection in Parkinson's disease with emotional stress

An Antisense Oligonucleotide-Loaded Blood–Brain Barrier Penetrable Nanoparticle Mediating Recruitment of Endogenous Neural Stem Cells for the Treatment of Parkinson’s Disease

Co-administration of Nanowired DL-3-n-Butylphthalide (DL-NBP) Together with Mesenchymal Stem Cells, Monoclonal Antibodies to Alpha Synuclein and TDP-43 (TAR DNA-Binding Protein 43) Enhance Superior Neuroprotection in Parkinson's Disease Following Concussive Head Injury

Co-administration of dl-3-n-butylphthalide and neprilysin is neuroprotective in Alzheimer disease associated with mild traumatic brain injury

Co-administration of TiO2-nanowired dl-3-n-butylphthalide (dl-NBP) and mesenchymal stem cells enhanced neuroprotection in Parkinson's disease exacerbated by concussive head injury

Emerging Nanotechnology for Treatment of Alzheimer’s and Parkinson’s Disease

Ginsenoside Rg1 ameliorates stress-exacerbated Parkinson's disease in mice by eliminating RTP801 and α-synuclein autophagic degradation obstacle

Emerging Nanotechnology for Treatment of Alzheimer's and Parkinson's Disease

Antioxidant Nanoparticles for Concerted Inhibition of α-Synuclein Fibrillization, and Attenuation of Microglial Intracellular Aggregation and Activation

Membrane phospholipid peroxidation promotes loss of dopaminergic neurons in psychological stress‐induced Parkinson's disease susceptibility

Dl-3-n-Butylphthalide Rescues Dopaminergic Neurons in Parkinson's Disease Models by Inhibiting the NLRP3 Inflammasome and Ameliorating Mitochondrial Impairment

Dl-3-n-Butylphthalide Rescues Dopaminergic Neurons in Parkinson’s Disease Models by Inhibiting the NLRP3 Inflammasome and Ameliorating Mitochondrial Impairment

Brain delivery of fibronectin through bioactive phosphorous dendrimers for Parkinson's disease treatment via cooperative modulation of microglia

Chronic Stress and Parkinson's Disease

The Effects of Stress on Lewy Pathology in Dopamine Neurons

Novel drug delivery systems of β2 adrenoreceptor agonists to suppress SNCA gene expression and mitochondrial oxidative stress in Parkinson's disease management

Microfluidics-enabled mesenchymal stem cell derived Neuron like cell membrane coated nanoparticles inhibit inflammation and apoptosis for Parkinson's Disease

Recent advances of nanomaterials for intervention in Parkinson's disease in the context of anti-inflammation

An upconversion nanoplatform based multi-effective theatment for Parkinson’s disease

Novel drug delivery systems of β2 adrenoreceptor agonists to suppress SNCA gene expression and mitochondrial oxidative stress in Parkinson’s disease management

DL-3-n-Butylphthalide Ameliorates Post-stroke Emotional Disorders by Suppressing Neuroinflammation and PANoptosis